224 related articles for article (PubMed ID: 21116263)
1. The therapeutic potential of κ-opioids for treatment of pain and addiction.
Chavkin C
Neuropsychopharmacology; 2011 Jan; 36(1):369-70. PubMed ID: 21116263
[No Abstract] [Full Text] [Related]
2. International Narcotics Research Conference (INRC) 2006.
Chavkin C
IDrugs; 2006 Oct; 9(10):693-5. PubMed ID: 17016774
[No Abstract] [Full Text] [Related]
3. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
Carlezon WA; Krystal AD
Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
[TBL] [Abstract][Full Text] [Related]
4. Selective kappa opioid antagonists for treatment of addiction, are we there yet?
Helal MA; Habib ES; Chittiboyina AG
Eur J Med Chem; 2017 Dec; 141():632-647. PubMed ID: 29107424
[TBL] [Abstract][Full Text] [Related]
5. Targeting opioid receptors: A new treatment for brain disorders.
Rahman S
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):128. PubMed ID: 20401980
[No Abstract] [Full Text] [Related]
6. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.
Jacobson ML; Browne CA; Lucki I
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():615-636. PubMed ID: 31914893
[TBL] [Abstract][Full Text] [Related]
7. Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.
Crowley NA; Kash TL
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():51-60. PubMed ID: 25592680
[TBL] [Abstract][Full Text] [Related]
8. Role of kappa-opioid receptors in stress and anxiety-related behavior.
Van't Veer A; Carlezon WA
Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of the kappa opioid receptor.
Urbano M; Guerrero M; Rosen H; Roberts E
Bioorg Med Chem Lett; 2014 May; 24(9):2021-32. PubMed ID: 24690494
[TBL] [Abstract][Full Text] [Related]
10. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.
Mendelson J; Flower K; Pletcher MJ; Galloway GP
Exp Clin Psychopharmacol; 2008 Oct; 16(5):435-41. PubMed ID: 18837640
[TBL] [Abstract][Full Text] [Related]
11. Cyclazocine revisited.
Archer S; Glick SD; Bidlack JM
Neurochem Res; 1996 Nov; 21(11):1369-73. PubMed ID: 8947927
[TBL] [Abstract][Full Text] [Related]
12. [Endorphins in psychiatry].
Lajeunesse C; Villeneuve A
Sem Hop; 1982 Dec; 58(44):2581-7. PubMed ID: 6297051
[No Abstract] [Full Text] [Related]
13. The emerging therapeutic roles of κ-opioid agonists.
Jones MR; Kaye AD; Kaye AJ; Urman RD
J Opioid Manag; 2016; 12(2):101-7. PubMed ID: 27194194
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the antidysrhythmic effects of delta- and kappa-opioid receptor agonists and antagonists on calcium chloride-, adrenaline- and ischemia/reperfusion-induced arrhythmias in rats.
Valtchanova-Matchouganska A; Missankov A; Ojewole JA
Methods Find Exp Clin Pharmacol; 2004; 26(1):31-8. PubMed ID: 14988739
[TBL] [Abstract][Full Text] [Related]
15. The role of the dynorphin/κ opioid receptor system in anxiety.
Hang A; Wang YJ; He L; Liu JG
Acta Pharmacol Sin; 2015 Jul; 36(7):783-90. PubMed ID: 25982631
[TBL] [Abstract][Full Text] [Related]
16. Kappa opioids as potential treatments for stimulant dependence.
Prisinzano TE; Tidgewell K; Harding WW
AAPS J; 2005 Oct; 7(3):E592-9. PubMed ID: 16353938
[TBL] [Abstract][Full Text] [Related]
17. Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone.
Ossipov MH; Kovelowski CJ; Wheeler-Aceto H; Cowan A; Hunter JC; Lai J; Malan TP; Porreca F
J Pharmacol Exp Ther; 1996 May; 277(2):784-8. PubMed ID: 8627559
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats.
Marín S; Marco E; Biscaia M; Fernández B; Rubio M; Guaza C; Schmidhammer H; Viveros MP
Pharmacol Biochem Behav; 2003 Feb; 74(3):649-56. PubMed ID: 12543231
[TBL] [Abstract][Full Text] [Related]
19. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A; Picciotto MR
CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):225-32. PubMed ID: 16611095
[TBL] [Abstract][Full Text] [Related]
20. Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease.
Parker KE; Sugiarto E; Taylor AMW; Pradhan AA; Al-Hasani R
Mol Pharmacol; 2020 Oct; 98(4):433-444. PubMed ID: 32958571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
